Skip to main content

Table 2 Relative risk of all-grade and high-grade (grade ≥ 3) hypertension of several VSP inhibitor agents, described in meta-analyses

From: Hypertension in cancer patients treated with anti-angiogenic based regimens

 

All grade hypertension

High grade hypertension

 

RRa

95 % CI

p Value

RRa

95 % CI

p Value

Bevacizumab [33]

3.02

2.24–4.07

<0.001

5.28

4.15–6.71

0.001

Sunitinib [52]

3.44

0.62–19.15

0.16

22.72

4.48–115.29

<0.001

Axitinib [38]

3.00

1.29–6.97

0.01

1.71

1.21–2.43

0.003

Sorafenib [62]

3.07

2.05–4.60

<0.01

3.31

2.21–4.95

<0.01

Pazopanib [65]

4.97

3.38–7.30

<0.001

2.87

1.16–7.11

0.023

Lenvatinib [69]

7.44

4.31–12.85

<0.001

18.2

5.90–56.32

<0.001

Vandetanib [36]

5.10

3.76–6.92

<0.001

8.06

3.41–19.04

0.001

Regorafenib [74]

3.76

2.35–5.99

<0.001

8.39

3.10–22.71

0.001

  1. Abbreviations: RR relative risk, CI confidence interval
  2. a Relative risk of new onset hypertension during trial period in interventional group compared to control